Get the Stockscreener App
1.71
5.56%
0.09
After Hours:
1.73
0.02
+1.17%
Invivyd Inc stock is traded at $1.71, with a volume of 2.16M.
It is up +5.56% in the last 24 hours and down -7.07% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.62
Open:
$1.65
24h Volume:
2.16M
Relative Volume:
0.63
Market Cap:
$482.20M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.8724
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+0.00%
1M Performance:
-7.07%
6M Performance:
+71.43%
1Y Performance:
+62.86%
1-Day Range:
$1.605
$1.73
1-Week Range:
$1.58
$1.76
52-Week Range:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.71 | 456.82M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
An Overview of Invivyd's Earnings - Benzinga
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How to listen to Invivyd's March 5 call on 2025 results - Stock Titan
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
New study maps COVID protection to antibody levels, not variants - Stock Titan
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd (IVVD) CFO Duke sells shares worth $63,350 By Investing.com - Investing.com South Africa
Invivyd CSO Allen sells shares worth $58,600 By Investing.com - Investing.com Nigeria
Invivyd CSO Allen sells shares worth $58,600 - Investing.com South Africa
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com Australia
Invivyd (NASDAQ: IVVD) legal chief sells shares in tax sell-to-cover plan - Stock Titan
Invivyd (IVVD) HR chief logs RSU vesting and tax sell-to-cover sales - Stock Titan
Timothy Edward Lee Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock - MarketBeat
RA Capital discloses 9.99% Invivyd (IVVD) stake via shares and warrants - Stock Titan
BVF group discloses 9% Invivyd (IVVD) stake via shares and warrants - Stock Titan
Invivyd’s COVID antibody VYD2311 receives FDA fast track - MSN
Point72 discloses 6% Invivyd (IVVD) ownership in Schedule 13G/A - Stock Titan
Can Invivyd Inc. navigate macro headwindsMarket Performance Recap & Safe Capital Investment Plans - mfd.ru
Does Invivyd Inc. have a sustainable dividendEarnings Overview Summary & Safe Capital Preservation Plans - mfd.ru
What makes Invivyd Inc. stock attractive to growth funds2025 Retail Activity & Daily Profit Maximizing Trade Tips - mfd.ru
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Invivyd prices $125M stock offering at $2.50 per share - MSN
Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa
Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy - Seeking Alpha
Invivyd aligns with FDA for Phase 3 vaccine trial - Traders Union
Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines - TradingView
Invivyd, Inc. Announces FDA Alignment on LIBERTY Phase 3 Clinical Trial for VYD2311, a Monoclonal Antibody Candidate for COVID-19 Prevention - Quiver Quantitative
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - The Manila Times
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 ... - Caledonian Record
FDA asks Invivyd to track myocarditis in new COVID antibody vs vaccine trial - Stock Titan
Invivyd Reports Strong Q3 Growth and Strategic Advances - MSN
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st
Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Invivyd shares edge higher on education campaign with Olympic star Lindsey Vonn - MSN
HC Wainwright Predicts Invivyd FY2030 Earnings - MarketBeat
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):